Overview

Treat-to-target With Secukinumab in Axial Spondyloarthritis

Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.
Phase:
Phase 4
Details
Lead Sponsor:
Professor Mikkel Østergaard
Collaborator:
Novartis Healthcare A/S
Treatments:
Antibodies, Monoclonal